Q
Qlaris Bio
Developing innovative therapies for ophthalmic diseases
About Qlaris Bio
Qlaris Bio is a clinical-stage biotechnology company focused on developing groundbreaking therapies for serious and debilitating eye diseases. The company is dedicated to preserving vision and preventing blindness through innovative treatments. Their primary product, QLS 111, is designed to lower intraocular pressure (IOP) by reducing episcleral venous pressure (EVP) and distal outflow resistance. This unique approach aims to achieve lower IOP targets than current therapies, offering new hope for patients with conditions like glaucoma.
Read full description
Qlaris Bio operates in the ophthalmic market, specifically targeting patients suffering from eye diseases that can lead to vision loss. Their clients include healthcare providers, ophthalmologists, and ultimately the patients who benefit from their therapies. The company’s business model revolves around the development and commercialization of its lead asset, QLS 111. By advancing this product through clinical trials and obtaining regulatory approvals, Qlaris Bio aims to bring it to market and generate revenue through sales and partnerships.
The company’s innovative approach is rooted in the combined expertise of its founders, who have identified a previously untreatable aspect of intraocular pressure management. This has allowed Qlaris Bio to create a therapy that could significantly improve the quality of life for patients with glaucoma and other eye diseases.
In summary, Qlaris Bio is a pioneering biotech firm committed to developing first-in-class therapies for eye diseases, with a focus on lowering intraocular pressure through innovative mechanisms. Their market includes healthcare providers and patients, and they generate revenue through the development and commercialization of their lead product, QLS 111.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Cambridge, United States
- Employees
- 12
- Open positions
- None listed
- Dealroom signal
- 83.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Ophthalmology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Qlaris Bio.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2024 | $24M | $96M | Mayo Clinic Business Development · Canaan · Correlation Ventures · New Leaf Venture Partners | ↗ |
| SPINOUT✓Other financing | Aug 2019 | $0 | — | University of Minnesota Twin Cities · Mayo Clinic | — |
Growth signals
Latest recorded traffic for Qlaris Bio is 2.9K monthly website visits, up 31.8% over the last three months. Qlaris Bio's team grew 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
Mayo Clinic Business Development
Canaan
Correlation Ventures
New Leaf Venture Partners
Aberdeen
Other known investors2 additional known investors
Mayo Clinic
University of Minnesota Twin Cities
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qlaris Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qlaris Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.